Gilead Sciences (NASDAQ:GILD) Issues Quarterly Earnings Results

Key Points

• Gilead beat Q1 estimates with $2.03 EPS (consensus $1.89) and $6.96B revenue, and raised 2026 revenue guidance to $30.0B–$30.4B after strong PrEP performance driven by the rapid YES2GO launch.
• The company withdrew prior profit guidance and now expects an adjusted FY2026 loss of $(1.05)–$(0.65), citing acquisition‑related charges and financing (including roughly $11.5B in upfronts) and an unusually high effective tax rate.
• Key pipeline and commercial catalysts remain: the once‑daily BIC/LEN is under priority FDA review with a decision expected in August, Trodelvy sales are up year‑over‑year, and recent acquisitions (Arcellx/Ouro/Tubulis) could support new launches into 2027 and beyond.

Gilead Sciences (NASDAQ:GILD - Get Free Report) issued its earnings results on Thursday. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.89 by $0.14, Zacks reports. The firm had revenue of $6.96 billion for the quarter, compared to analysts' expectations of $6.91 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company's revenue was up 4.4% compared to the same quarter last year. During the same quarter last year, the business earned $1.81 earnings per share. Gilead Sciences updated its FY 2026 guidance to -1.050--0.650 EPS.

Here are the key takeaways from Gilead Sciences' conference call:

• Gilead raised 2026 revenue guidance by $400 million after a strong Q1, with updated 2026 base business sales of $29.4B–$29.8B and total product sales now expected at $30.0B–$30.4B, reflecting broad commercial execution.
• The U.S. PrEP franchise accelerated (PrEP sales +87% YoY) driven by YES2GO's rapid launch (Q1 sequential growth +72%), and Gilead raised YES2GO 2026 guidance to ~$1 billion with ~95% U.S. coverage and high $0 copay access.
• Key HIV pipeline catalysts remain on track: the once-daily bictegravir+lenacapavir (BIC/LEN) is under priority FDA review with a decision expected in August, and multiple long-acting oral/injectable programs could support new launches through 2033.
• Gilead closed Arcellx and is acquiring Ouro Medicines and Tubulis, and upfront acquired IPR&D and transaction financing (~$11.5B in upfronts and ~$9.50/share impact) drive a 2026 non‑GAAP EPS range of $(1.05)–$(0.65) and an unusually high effective tax rate (140%–190%).
• Oncology and cell therapy momentum continued: Trodelvy sales were +37% YoY with potential first‑line metastatic TNBC regulatory decisions in H2 2026, and anito‑cel (Arcellx) has a December PDUFA with revenue expected to begin in early 2027.

Gilead Sciences Stock Down 1.6%

GILD traded down $2.24 during trading on Thursday, hitting $134.06. The company had a trading volume of 8,889,606 shares, compared to its average volume of 5,546,303. The company has a market capitalization of $166.40 billion, a PE ratio of 19.80, a PEG ratio of 1.80 and a beta of 0.31. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. Gilead Sciences has a one year low of $95.29 and a one year high of $157.29. The firm's 50-day moving average price is $139.59 and its 200 day moving average price is $132.87.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on GILD shares. Morgan Stanley lifted their price objective on shares of Gilead Sciences from $171.00 to $175.00 and gave the stock an "overweight" rating in a research note on Tuesday, April 28th. Bank of America set a $162.00 target price on shares of Gilead Sciences and gave the stock a "buy" rating in a report on Wednesday, February 11th. Royal Bank Of Canada lifted their price target on shares of Gilead Sciences from $118.00 to $123.00 and gave the stock a "sector perform" rating in a research report on Tuesday, April 7th. Citigroup upped their price objective on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a "buy" rating in a research report on Monday, April 13th. Finally, Wall Street Zen raised Gilead Sciences from a "buy" rating to a "strong-buy" rating in a research note on Saturday, March 14th. Twenty-four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $157.35.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total value of $463,290.00. Following the sale, the chief financial officer owned 167,779 shares of the company's stock, valued at $25,910,110.97. This trade represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total value of $1,291,600.00. Following the transaction, the chief executive officer directly owned 632,567 shares of the company's stock, valued at $81,702,353.72. This represents a 1.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 63,000 shares of company stock worth $9,238,250. Corporate insiders own 0.30% of the company's stock.

Institutional Trading of Gilead Sciences

A number of hedge funds and other institutional investors have recently made changes to their positions in GILD. Mcguire Capital Advisors Inc. acquired a new position in shares of Gilead Sciences during the 4th quarter worth about $43,000. T. Rowe Price Investment Management Inc. raised its holdings in Gilead Sciences by 13.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 302,669 shares of the biopharmaceutical company's stock worth $37,150,000 after acquiring an additional 35,769 shares in the last quarter. Claris Financial LLC acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $371,000. TMB Capital Partners LLC acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $228,000. Finally, Axxcess Wealth Management LLC grew its stake in Gilead Sciences by 8.6% in the fourth quarter. Axxcess Wealth Management LLC now owns 14,526 shares of the biopharmaceutical company's stock valued at $1,783,000 after purchasing an additional 1,155 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q1 results beat estimates — Gilead reported $2.03 EPS vs. a $1.89 consensus and revenue of $6.96B vs. ~$6.91B, showing underlying quarter strength. Gilead Sciences (GILD) Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its 2026 sales forecast, indicating revenue strength despite other headwinds. Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions
• Neutral Sentiment: Full‑year revenue guidance was issued at roughly $30.0–30.4B, near analyst consensus — so sales expectations are roughly intact even as profit guidance shifted. Gilead Press Release / Slide Deck
• Neutral Sentiment: Shareholders approved the board and executive pay plans at the 2026 meeting — governance items cleared without disruption. Gilead Shareholders Back Board, Pay Plans at 2026 Meeting
• Negative Sentiment: Company withdrew prior profit guidance and now expects an adjusted FY2026 loss of $1.05 to $0.65 per share (versus prior ~$8.45–8.85 outlook and analyst expectations near $8.65), a dramatic revision that hits valuation and investor confidence. Gilead Sciences Expects Loss This Year on Acquired R&D Expenses
• Negative Sentiment: Management attributes the profit swing to acquisition‑related charges and financing costs tied to recent deals — these one‑time and financing items meaningfully depress reported earnings for the year. Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.